Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ )

0.2075 -0.0049 (-2.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Partners With Liquid Biosciences In Exclusive Relationship To Harness The Power Of Artificial Intelligence (AI) To Develop Next-Generation Colorectal Screening Test
The integration of Artificial Intelligence (AI) in biotechnology is rapidly gaining momentum, revolutionizing the field of life sciences. AI technologies, such as machine learning and deep learning... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
Collaboration to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processing 
From Mainz BioMed NV
Via GlobeNewswire
What 5 Analyst Ratings Have To Say About Mainz Biomed
Via Benzinga
Mainz Biomed’s (NASDAQ: MYNZ) ColoFuture Study Reveals “Groundbreaking Results”: ColoAlert® Raises The Bar For Colorectal Cancer Detection
--News Direct-- 
Via News Direct
Topics Death
Exposures Death
AI Meets Oncology! Mainz Biomed Inks Pact With Liquid Biosciences To Develop Next-Gen Colorectal Cancer Screening Test
Mainz Biomed N.V. (NASDAQ: MYNZ) inked a pact with Liquid Biosciences, a bio-analytics company leveraging its proprietary AI analysis technology platform (EMERGE), to enhance the  
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioNTech Shifted Its Focus To Innovative Oncology And Mainz Biomed Announced A Showcasing Of Its Revolutionary Colorectal Cancer Detection Test
On November 6th, BioNTech SE (NASADQ: SE) who partnered with Pfizer Inc (NYSE: PFE) in the making of a blockbuster COVID-19 vaccine, posted a surprise earnings with its latest quarterly report. 
Via Benzinga
Exposures COVID-19
Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed's (NASDAQ: MYNZ) ColoFuture Study Reveals "Groundbreaking Results": ColoAlert® Raises The Bar For Colorectal Cancer Detection
Throughout the world, colorectal cancer has emerged as the third most prevalent form of cancer. 
Via Benzinga
Splunk Layoffs 2023: What to Know About the Latest SPLK Job Cuts
Splunk layoffs are on the way for 7% of the cybersecurity company's global employees as it continues a restructuring plan. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Why Is WeWork (WE) Stock Down 38% Today?
WeWork stock is falling on Wednesday as investors in WE shares react to reports that the company is considering a bankruptcy filing. 
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
Why Is Paycom Software (PAYC) Stock Down 39% Today?
Paycom Software stock is falling hard on Wednesday as investors in PAYC go over the company's mixed earnings report for Q3 2023! 
Via InvestorPlace
Why Is Mainz Biomed (MYNZ) Stock Moving Today?
Mainz Biomed stock is on the move Wednesday as investors in MYNZ react to results from a colorectal cancer screening test campaign. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today! 
Via InvestorPlace
Today's Pharma Tales Of Loss And Success: Pfizer Swings To A Quarterly Loss And Mainz Biomed Reports Positive Interim Screening Campaign Results
As it struggles to navigate the rapid decline of its Covid-19 fame, Pfizer Inc (NYSE: PFE) reported a quarterly loss for the third quarter. 
Via Benzinga
Exposures COVID-19
Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
Almost half of Zöller-KipperGmbH’s employees in Germany participated in the screening program so far using ColoAlert®, Mainz Biomed’s user-friendly, at-home colorectal cancer (CRC) screening test 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
From Mainz BioMed NV
Via GlobeNewswire
Johnson & Johnson Was Saved By Its Focus On MedTech And Innovative Medicine
Johnson & Johnson (NYSE: JNJ) reported its third quarter results that topped Wall Street’s expectations while also lifting its full year guidance fueled by a strong performance of its pharmaceutical... 
Via Benzinga
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
Mainz Biomed team members will be available throughout the event at the Company’s booth located in Hall C, Stand C3-92 
From Mainz BioMed NV
Via GlobeNewswire
Big Pharma Could Transform Into BioTech Pharma
As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall... 
Via Benzinga
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Continues To Transform Early Cancer Detection Across The Globe
While Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) are making great progress in cancer treatments, the importance of early detection in combating this disease cannot be overstated. 
Via Benzinga
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
Strategic Collaboration Elevates Early Cancer Detection, Bringing State-of-the-Art Diagnostic Capabilities to Romanian Population 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed To Present The Power Of mRNA That Promises To Revolutionize Medicine
Pharma companies across the globe, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), are harnessing the potential of mRNA which is creating plenty of space for scientific improvement in... 
Via Benzinga
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
From Mainz BioMed NV
Via GlobeNewswire
AI To Revolutionize Clinical Trials And Diagnostics
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
From Mainz BioMed NV
Via GlobeNewswire
Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of... 
Via Benzinga
Mainz Biomed Paves The Way For Early Colorectal Cancer Diagnosis And Even Prevention
By the words of Dr. Ruediger Dahlke, cancer is a caricature of today’s modern society as it reflects the dark side ‘growth’. Our civilization is clearly more on the dark side of growth with technology... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.